Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVINCY trial
NL-OMON50886Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant and fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Started Feb 2022; status: recruiting.
02
Drugs
aprepitantfosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON50886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50886.